Asymmetric dimethylarginine (ADMA) is a naturally occurring modified amino acid in human blood. It inhibits the production of nitric oxide, a key regulator of the vascular tone, and may thereby contribute importantly to the process of atherosclerosis.[@b1]--[@b3] ADMA has been shown to correlate with various measures of subclinical atherosclerosis, including carotid intima-media thickness[@b4] and flow-mediated dilatation.[@b5]--[@b8] Additionally, a growing number of studies suggest that high values of circulating ADMA concentration are associated with the incidence of cardiovascular disease (CVD) outcomes. However, interpretation of these studies has been complicated because they differ in relation to the population studied (eg, approximately general population versus patients with pre-existing CVD or kidney disease), the disease outcomes assessed (eg, "hard" CVD composed of coronary heart disease and stroke versus wider definitions), and/or the analytical approaches used (eg, different adjustment for potential confounders).[@b9] Furthermore, as previously published reports typically comprised only a few hundred incident CVD outcomes, they were insufficiently powered to investigate associations by clinically relevant characteristics. Finally, the extent to which associations of ADMA are consistent with those of its related isomer symmetric dimethylarginine (SDMA) has never been quantitatively reviewed.

To help clarify the evidence, we have conducted a systematic review and meta-analysis of available data on ADMA and SDMA in relation to CVD outcomes. We had 3 principal aims. First, to quantify associations of circulating ADMA concentration with incident CVD, coronary heart disease (CHD), and stroke in a consistent manner. Second, to evaluate these associations under a wide range of circumstances. Third, to compare associations for ADMA with those for SDMA.

Methods
=======

Literature Search and Study Selection
-------------------------------------

We sought prospective studies that had been published between January 1970 and January 2015 and reported on associations of dimethylarginines with incident CVD (defined as CHD or stroke). Systematic searches of PubMed, Web of Science, and EMBASE were supplemented by scanning reference lists of articles identified (including relevant reviews) and by correspondence with several study investigators. The search strategy is detailed in Table[1](#tbl1){ref-type="table"}. Studies were eligible for inclusion if they had recorded events over at least 1 year of follow-up and involved any of the following types of study populations: approximately general population (ie, participants not selected on the basis of preexisting disease at baseline), populations with pre-existing cardiovascular diseases (eg, people with CHD or stroke or peripheral artery disease), or populations with pre-existing kidney disease (eg, people with chronic kidney disease or a kidney transplant). We only included studies that conformed to our pre-specified CVD outcome definition, and excluded studies that used broader outcome definitions (involving incident heart failure, cardiac arrhythmia, peripheral arterial disease, venous thrombosis, pulmonary embolism, or all-cause mortality),[@b10]--[@b22] had a follow-up of less than 1 year,[@b23] or both.[@b24]--[@b26] The meta-analysis was conducted following the PRISMA guidelines.

###### 

Search Terms Used for the Systematic Literature Search

  Database                                                       Search Terms
  -------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PubMed                                                         ("ADMA" \[All Fields\] OR "N, N-dimethylarginine" \[Supplementary Concept\] OR "N, N-dimethylarginine" \[All Fields\] OR "asymmetric dimethylarginine" \[All Fields\] OR "SDMA" \[All Fields\]) AND ("Cardiovascular Diseases" \[Mesh\] OR "Coronary Artery Disease" \[MeSH\] OR "Atherosclerosis" \[MeSH\] OR "Coronary Disease" \[MeSH\] OR "Myocardial Infarction" \[MeSh\] OR "Myocardial Ischemia" \[MeSH\] OR "Stroke" \[MeSH\] OR "Cerebrovascular" \[All fields\]) NOT ("Animals"\[MeSH\] NOT "Humans"\[MeSH\])
  Web of Science (SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH)   TS=("ADMA" OR "N, N-dimethylarginine" OR "asymmetric dimethylarginine" OR "SDMA") AND TS=("Cardiovascular Diseases" OR "Coronary Artery Disease" OR "Atherosclerosis" OR "Coronary Disease" OR "Myocardial Infarction" OR "Myocardial Ischemia" OR "Stroke" OR "Cerebrovascular")
  EMBASE                                                         ("ADMA" OR "N, N-dimethylarginine" OR "asymmetric dimethylarginine" OR "SDMA").af AND ("Cardiovascular Diseases" OR "Coronary Artery Disease" OR "Atherosclerosis" OR "Coronary Disease" OR "Myocardial Infarction" OR "Myocardial Ischemia" OR "Stroke" OR "Cerebrovascular").af

The search was conducted on January 14, 2015. No language restrictions were applied.

Data Extraction
---------------

Descriptive and quantitative data were extracted by consensus among 2 independent reviewers using standardized data extraction protocols. If multiple publications on the same study were available, the most up-to-date or comprehensive information was used. Retrieved study characteristics included study design, geographical location, population source (ie, population registers, general practice registers, or hospital-based registers), baseline disease status, study size, average age at baseline, and proportion of male participants. Additionally, information on the measurement of dimethylarginines was obtained, including sample type (ie, plasma/serum), storage temperature, and assay details (ie, assay method and manufacturer/source). Finally, data in relation to follow-up were extracted, including duration of follow-up, the specific composition of reported endpoints, number of incident outcomes, effect sizes, and degree of statistical adjustment of reported associations. The degree of adjustment was classified as "o" when risk ratio (RRs) estimates were unadjusted; "+" when RRs were adjusted for age and sex; "++" when further adjusted for at least 2 conventional CVD risk factors (ie, smoking, diabetes, blood pressure, or circulating lipid levels); and "+++" when additionally adjusted for other factors.

Statistical Analysis
--------------------

Analyses involved only within-study comparisons (ie, cases and controls were directly compared only within each cohort) to limit potential biases. To enable a consistent approach to analysis, RRs and 95% confidence intervals (CIs) in each study were standardized to a common scale, ie, to reflect a comparison of the top third with the bottom third of the population's baseline distribution of circulating ADMA or SDMA concentrations, employing statistical methods described elsewhere.[@b27] These comparisons correspond approximately to a difference of 0.67 μmol/L in ADMA and 0.53 μmol/L in SDMA concentrations, respectively. Summary RRs were calculated by pooling study-specific estimates by random-effects meta-analysis, with hazard ratios and odds ratios assumed to approximate the same measure of relative risk. One study provided supplementary unpublished tabular data on 10 years of follow-up (as opposed to 5 years in the original published report).[@b28] When studies reported RRs of various levels of adjustment, the most adjusted estimate was used. Consistency of findings across studies was assessed with standard χ^2^ tests and the I^2^ statistic.[@b29] Subgroup analyses were conducted using meta-regression across pre-specified study-level characteristics.[@b30] Evidence of publication bias was assessed using funnel plots and Egger's asymmetry test.[@b31] Duval and Tweedie's nonparametric "trim and fill" method was applied to take into account the effect of publication bias on pooled RRs.[@b32] All analyses were performed using Stata release 12.1 (StataCorp, College Station, TX). All statistical tests were 2-sided and used a significance level of *P*\<0.05.

Results
=======

General Characteristics of the Included Studies
-----------------------------------------------

We screened 3180 records ([Figure 1](#fig01){ref-type="fig"}) and identified 22 eligible prospective studies[@b28],[@b33]--[@b53] reporting on a total of 19 842 participants (Tables[2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}). During a mean follow-up duration of 7.1 years, a total of 2339 CVD, 997 CHD, and 467 stroke outcomes were recorded. Sixteen studies were based in Europe, 4 in North America, and 2 in Asia. Participants were typically sourced from population registers (7111 participants), general practitioner registers (2447 participants), or from hospitals (10 284 participants). Eight studies were based on participants from general populations (8298 participants); 9 studies involved people with pre-existing CVD (8043 participants); and 5 studies involved people with pre-existing kidney disease (3501 participants). All but 3 studies reported effect estimates adjusted for age, sex, and at least 2 other conventional CVD risk factors (ie, smoking, diabetes, blood pressure, or circulating lipid levels). Fourteen studies reported effect estimates further adjusted for additional characteristics, such as body mass index, C-reactive protein, social status, physical activity, or estimated glomerular filtration rate. On average, participants were 58 years old at baseline; 58% were male. The pooled mean and standard deviation was 0.71±0.31 μmol/L for circulating ADMA and 0.56±0.24 μmol/L for SDMA concentrations.

###### 

Study Design and Assay Methods of the 22 Prospective Studies

  Study Acronym                                  Study Design     Measurement of Dimethylarginines                                                                                                                                                       
  ---------------------------------------------- ---------------- ---------------------------------- --------------------- ------------------- -------- ---- ----- -------- ------ ---------- ------------------ --------------------------------------- ---------------------------------------
  General population                                                                                                                                                                                                                                     
   BRUNECK[@b28]                                 Italy            2000--2010                         Population register   ---                 685      66   48    Plasma   −70°   LC-MS/MS   ABSciex API 4000   0.97                                    0.65
   DHS[@b33]                                     US               2000--2002                         Population register   ---                 3523     43   44    Plasma   −70°   LC-MS/MS   Varian 1200L       N/R                                     N/R
   GetABI (no PAD)[@b34]                         Germany          2001--2006                         GP register           ---                 1187     72   42    Plasma   N/R    LC-MS/MS   Varian 1200L       0.60                                    0.48
   INCHIANTI[@b35]                               Italy            1998--2000                         Population register   ---                 1025     75   44    Serum    −80°   LC-MS/MS   Varian 1200L       0.5                                     ---
   KIHD[@b36]                                    Finland          1991--1993                         Population register   ---                 150      58   100   Serum    −80°   HPLC       N/R                0.51                                    ---
   KVINNOSTUDIEN[@b37]                           Sweden           1968--1969                         Population register   ---                 880      46   0     Serum    −20°   HPLC       In house           0.62                                    ---
   MDC[@b38]                                     Sweden           1991--1996                         Population register   ---                 506      58   40    Plasma   N/R    LC-MS/MS   N/R                N/R                                     ---
   MONICA/KORA[@b39]                             Germany          1989--1995                         Population register   ---                 342      61   100   Plasma   −70°   ELISA      DLD Diagnostica    0.79                                    ---
  Populations with pre-existing CVD                                                                                                                                                                                                                      
   AtheroGene[@b40]                              Germany          1999--2004                         Hospital              Confirmed CAD       1874     61   79    Serum    −80°   ELISA      DLD Diagnostica    0.68                                    ---
   BECAC[@b41]                                   Norway           2000--2004                         Hospital              Suspected CAD       1364     61   75    Plasma   −80°   LC-MS/MS   Bevital AS         0.59[\*](#tf2-2){ref-type="table-fn"}   ---
   Cavalca et al[@b42]                           Italy            2005--2007                         Hospital              NSTEMI              104      67   74    Plasma   −80°   HPLC       ESA Biosciences    0.43                                    0.49
   Cavusoglu et al[@b43]                         US               1999--2002                         Hospital              Suspected CAD       182      65   100   Plasma   −70°   ELISA      DLD Diagnostica    N/R                                     ---
   GeneBank[@b44]                                US               N/R                                Hospital              Suspected CAD       1011     64   47    Plasma   −80°   HPLC       In-house           1.03[\*](#tf2-2){ref-type="table-fn"}   0.65[\*](#tf2-2){ref-type="table-fn"}
   GetABI (PAD)[@b34]                            Germany          2001--2006                         GP register           PAD                 1260     74   46    Plasma   N/R    LC-MS/MS   Varian 1200L       0.63                                    0.51
   KAROLA[@b45]                                  Germany          1999--2000                         Hospital              CHD                 1148     59   85    Plasma   −80°   LC-MS/MS   Varian 1200L       0.57                                    0.53
   Lu et al[@b46]                                Taiwan           1999--2001                         Hospital              Suspected CAD       103      71   87    Plasma   −70°   HPLC       Waters 470         0.56                                    0.58
   Lu et al[@b47]                                Taiwan           2006--2009                         Hospital              Suspected CAD       997      67   79    Plasma   −70°   HPLC       Waters 470         0.45                                    ---
  Populations with pre-existing kidney disease                                                                                                                                                                                                           
   ALERT[@b48]                                   Multi-national   1996--1997                         Hospital              KTx                 1847     50   66    Serum    −80°   HPLC       N/R                0.77[\*](#tf2-2){ref-type="table-fn"}   ---
   CREED[@b49],[@b50]                            Italy            1997--1998                         Hospital              CKD stage 5         283      61   56    Plasma   −80°   HPLC       Varian             3.03[\*](#tf2-2){ref-type="table-fn"}   ---
   Ignjatovic et al[@b51]                        Serbia           N/R                                Hospital              Hemodialysis        153      58   70    Plasma   N/R    HPLC       Agilent 1200       0.44                                    0.94
   MDRD[@b52]                                    US               1989--1993                         Hospital              CKD stage 3/4       821      52   60    Serum    −70°   ELISA      DLD Diagnostica    0.73                                    ---
   SDC[@b53]                                     Denmark          1993                               Hospital              Diab. nephropathy   397      42   61    Plasma   N/R    HPLC       N/R                0.46                                    ---
  Total                                                           1968--2010                                                                   19 842   58   58                                                  0.71                                    0.56

Full study names: ALERT, Assessment of Lescol in Renal Transplantation Study; BECAC, Bergen coronary angiography cohort; BRUNECK, Bruneck Study; CREED, Cardiovascular Risk Extended Evaluation in Dialysis; DHS, Dallas Heart Study; GetABI, German Epidemiological Trial on Ankle Brachial Index; INCHIANTI, Invecchiare in Chianti Study; KAROLA, Langzeiterfolge der KARdiOLogischen Anschlussheilbehandlung; KIHD, Kuopio Ischaemic Heart Disease Study; KVINNOSTUDIEN, Kvinnostudien Population Study of Women in Gothenburg; MDC, Malmö Diet and Cancer Cardiovascular Cohort; MDRD, Modification of Diet in Renal Disease Study; MONICA/KORA, Monitoring of Trends and Determinants in Cardiovascular Disease Augsburg; SDC, Steno Diabetes Center. ADMA indicates asymmetric dimethylarginine; CAD, coronary artery disease; CHD, coronary heart disease; CKD, chronic kidney disease; CVD, cardiovascular disease; ELISA, enzyme-linked immunosorbent assay; GP, general practitioner; HPLC, high-performance liquid chromatography; KTx, kidney transplant; LC-MS/MS, liquid chromatography with tandem mass spectrometry; N/R, not reported; NSTEMI, non ST-elevation myocardial infarction; PAD, peripheral arterial disease; SDMA, symmetric dimethylarginine.

Median.

###### 

Follow-Up and Incident Outcomes in the 22 Prospective Studies

  Study Acronym                                  Median Duration of Follow-Up, Years     Definition of Incident Cardiovascular Outcomes   No. of Incident Cardiovascular Outcomes                                        
  ---------------------------------------------- --------------------------------------- ------------------------------------------------ ----------------------------------------- ----- ----- ----- ----- ------ ----- -----
  General population                                                                                                                                                                                                     
   BRUNECK[@b28]                                 10.0[\*](#tf3-2){ref-type="table-fn"}   No                                               Yes                                       Yes   Yes   Yes   No    90     39    46
   DHS[@b33]                                     7.4                                     Yes                                              No                                        No    No    No    No    62     ---   ---
   GetABI (No PAD)[@b34]                         5.0[\*](#tf3-2){ref-type="table-fn"}    No                                               Yes                                       Yes   Yes   Yes   Yes   131    99    33
   INCHIANTI[@b35]                               9.2                                     Yes                                              No                                        No    No    No    No    141    ---   ---
   KIHD[@b36]                                    6.0[\*](#tf3-2){ref-type="table-fn"}    Yes                                              Yes                                       No    No    No    No    ---    45    ---
   KVINNOSTUDIEN[@b37]                           24.0[\*](#tf3-2){ref-type="table-fn"}   No                                               Yes                                       Yes   No    Yes   Yes   101    58    43
   MDC[@b38]                                     12.0[\*](#tf3-2){ref-type="table-fn"}   Yes                                              Yes                                       Yes   No    Yes   Yes   253    ---   ---
   MONICA/KORA[@b39]                             6.2                                     Yes                                              Yes                                       No    No    No    No    ---    88    ---
  Populations with pre-existing CVD                                                                                                                                                                                      
   AtheroGene[@b40]                              2.6[†](#tf3-3){ref-type="table-fn"}     Yes                                              Yes                                       No    No    Yes   Yes   159    ---   45
   BECAC[@b41]                                   5.3[†](#tf3-3){ref-type="table-fn"}     Yes                                              Yes                                       No    No    No    No    ---    129   ---
   Cavalca et al[@b42]                           1.8                                     Yes                                              Yes                                       No    No    No    No    ---    24    ---
   Cavusoglu et al[@b43]                         2.0[\*](#tf3-2){ref-type="table-fn"}    Yes                                              Yes                                       No    No    No    No    ---    37    ---
   GeneBank[@b44]                                3.0[\*](#tf3-2){ref-type="table-fn"}    No                                               Yes                                       No    No    Yes   Yes   64     ---   ---
   GetABI (PAD)[@b34]                            5.0[\*](#tf3-2){ref-type="table-fn"}    No                                               Yes                                       Yes   Yes   Yes   Yes   263    197   65
   KAROLA[@b45]                                  8.1                                     Yes                                              Yes                                       No    No    Yes   Yes   150    ---   ---
   Lu et al[@b46]                                1.3                                     Yes                                              Yes                                       Yes   Yes   No    No    51     ---   ---
   Lu et al[@b47]                                2.4                                     Yes                                              Yes                                       No    Yes   Yes   Yes   144    ---   ---
  Populations with pre-existing kidney disease                                                                                                                                                                           
   ALERT[@b48]                                   6.7[†](#tf3-3){ref-type="table-fn"}     No                                               Yes                                       Yes   Yes   Yes   Yes   455    281   174
   CREED[@b49],[@b50]                            10.9[\*](#tf3-2){ref-type="table-fn"}   No                                               No                                        No    No    Yes   Yes   ---    ---   61
   Ignjatovic et al[@b51]                        3.0[\*](#tf3-2){ref-type="table-fn"}    Yes                                              No                                        No    No    No    No    37     ---   ---
   MDRD[@b52]                                    9.5                                     Yes                                              No                                        No    No    No    No    122    ---   ---
   SDC[@b53]                                     11.3                                    No                                               Yes                                       Yes   Yes   Yes   Yes   116    ---   ---
  Total                                          7.1                                                                                                                                                        2339   997   467

ALERT indicates Assessment of Lescol in Renal Transplantation Study; AtheroGene; BECAC, Bergen coronary angiography cohort; BRUNECK, Bruneck Study; CHD, coronary heart disease; CKD, chronic kidney disease; CREED, Cardiovascular Risk Extended Evaluation in Dialysis; CVD, cardiovascular disease; DHS, Dallas Heart Study; GetABI, German Epidemiological Trial on Ankle Brachial Index; INCHIANTI, Invecchiare in Chianti Study; KAROLA, Langzeiterfolge der KARdiOLogischen Anschlussheilbehandlung; KIHD, Kuopio Ischaemic Heart Disease Study; KVINNOSTUDIEN, Kvinnostudien Population Study of Women in Gothenburg; MDC, Malmö Diet and Cancer Cardiovascular Cohort; MDRD, Modification of Diet in Renal Disease Study; MI, myocardial infarction; MONICA/KORA, Monitoring of Trends and Determinants in Cardiovascular Disease Augsburg; PAD, peripheral arterial disease; SDC, Steno Diabetes Center.
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Mean.

![Study flow diagram. ADMA indicates asymmetric dimethylarginine; CVD, cardiovascular disease; SDMA, symmetric dimethylarginine.](jah30004-e001833-f1){#fig01}

Circulating ADMA Concentration And Risk of Cardiovascular Outcomes
------------------------------------------------------------------

In a comparison of individuals in the top with those in the bottom third of baseline values of ADMA, the combined RRs were 1.42 (95% confidence interval: 1.29 to 1.56) for CVD, 1.39 (1.19 to 1.62) for CHD, and 1.60 (1.33 to 1.91) for stroke (Figures[2](#fig02){ref-type="fig"} and [3](#fig03){ref-type="fig"}). The level of between-study heterogeneity was low with I^2^ values ranging from 0% to 16%. The magnitude of association was comparable in studies conducted in the general population (RR for CVD, 1.35 \[1.18 to 1.54\]), studies of individuals with pre-existing CVD (1.47 \[1.16 to 1.87\]), and studies in individuals with pre-existing kidney disease (1.52 \[1.26 to 1.84\]) ([Figure 4](#fig04){ref-type="fig"}). Furthermore, there was no evidence for a difference in associations according to population source, geographical location, sample type, assay method, length of follow-up, number of CVD outcomes, and level of statistical adjustment employed (for meta-regression *P*\>0.05 for all, [Figure 4](#fig04){ref-type="fig"}). The magnitude of association between ADMA and CVD risk did not differ according to mean age and sex distribution of the study population ([Figure 4](#fig04){ref-type="fig"}).

![Combined RRs (95% CI) for cardiovascular outcomes in individuals in the top compared with those in the bottom third of ADMA and SDMA concentration. When analysis was restricted to studies that reported on both methylarginines (for direct comparison), the RR of ADMA was 1.40 (1.16, 1.68) for CVD, 1.24 (1.01, 1.52) for CHD, and 1.57 (1.12, 2.20) for stroke and the RR of SDMA was 1.32 (0.92, 1.90) for CVD, 1.44 (0.77, 2.67) for CHD, and 1.31 (0.83, 2.07) for stroke. ADMA indicates asymmetric dimethylarginine; CHD, coronary heart disease; CVD, cardiovascular disease; RR, risk ratio; SDMA, symmetric dimethylarginine.](jah30004-e001833-f2){#fig02}

![Reported RRs (95% CI) for cardiovascular outcomes in individuals in the top compared with those in the bottom third of ADMA concentration. I^2^ (95% CI) was 16% (0%, 53%) for CVD, 14% (0%, 55%) for CHD and 0% (0%, 71%) for stroke. ADMA indicates asymmetric dimethylarginine; ALERT, Assessment of Lescol in Renal Transplantation Study; BECAC, Bergen coronary angiography cohort; BRUNECK, Bruneck Study; CHD, coronary heart disease; CREED, Cardiovascular Risk Extended Evaluation in Dialysis; CVD, cardiovascular disease; DHS, Dallas Heart Study; GetABI, German Epidemiological Trial on Ankle Brachial Index; INCHIANTI, Invecchiare in Chianti Study; KAROLA, Langzeiterfolge der KARdiOLogischen Anschlussheilbehandlung; KIHD, Kuopio Ischaemic Heart Disease Study; KVINNOSTUDIEN, Kvinnostudien Population Study of Women in Gothenburg; MDC, Malmö Diet and Cancer Cardiovascular Cohort; MDRD, Modification of Diet in Renal Disease Study; MONICA/KORA, Monitoring of Trends and Determinants in Cardiovascular Disease Augsburg; PAD, peripheral arterial disease; RRs, risk ratios; SDC, Steno Diabetes Center.](jah30004-e001833-f3){#fig03}

![Association of ADMA concentration with CVD risk according to different clinically relevant characteristics. + indicates adjusted for age and sex; ++, further adjusted for at least 2 conventional CVD risk factors; +++, additionally adjusted for other factors; ADMA, asymmetric dimethylarginine; CVD, cardiovascular disease; ELISA, enzyme-linked immunosorbent assay; GP, general practitioner; HPLC, high-performance liquid chromatography; LC-MS/MS, liquid chromatography with tandem mass spectrometry; o, unadjusted; RR, risk ratio.](jah30004-e001833-f4){#fig04}

We observed some evidence for publication bias for the association of ADMA with risk of CVD and CHD outcomes (*P*~Egger~=0.009 and 0.033) ([Figure 5](#fig05){ref-type="fig"}). Application of the "trim and fill" method suggested that ≈5 studies for CVD and ≈2 studies for CHD were missing due to publication bias. Addition of these theoretical studies to the meta-analyses would attenuate RRs slightly, with RRs of 1.35 (1.20 to 1.51) and 1.35 (1.11 to 1.64) for CVD and CHD, respectively. There was no evidence for publication bias across studies reporting on stroke outcomes.

![Funnel plots of reported associations between ADMA and cardiovascular outcomes. The dotted lines show pseudo 95% confidence intervals around the overall pooled estimate. *P* values are from Egger's asymmetry test of associations. ADMA indicates asymmetric dimethylarginine; ALERT, Assessment of Lescol in Renal Transplantation Study; BECAC, Bergen coronary angiography cohort; BRUNECK, Bruneck Study; CHD, coronary heart disease; CREED, Cardiovascular Risk Extended Evaluation in Dialysis; CVD, cardiovascular disease; DHS, Dallas Heart Study; GetABI, German Epidemiological Trial on Ankle Brachial Index; KAROLA, Langzeiterfolge der KARdiOLogischen Anschlussheilbehandlung; KVINNOSTUDIEN, Kvinnostudien Population Study of Women in Gothenburg; MDC, Malmö Diet and Cancer Cardiovascular Cohort; MDRD, Modification of Diet in Renal Disease Study; MONICA/KORA, Monitoring of Trends and Determinants in Cardiovascular Disease Augsburg; PAD, peripheral arterial disease; RR, risk ratio; SDC, Steno Diabetes Center.](jah30004-e001833-f5){#fig05}

Circulating SDMA Concentration and Risk of Cardiovascular Outcomes
------------------------------------------------------------------

In a subset of 9 studies with available information on baseline SDMA concentration, the combined RRs comparing the top with the bottom third of SDMA concentration were 1.32 (0.92 to 1.90) for CVD, 1.44 (0.77 to 2.67) for CHD, and 1.31 (0.83 to 2.07) for stroke (Figures[2](#fig02){ref-type="fig"} and [6](#fig06){ref-type="fig"}). The level of between-study heterogeneity was moderate with I^2^ values ranging from 27% to 77%.

![Reported RRs (95% CI) for cardiovascular outcomes in individuals in the top compared with those in the bottom third of SDMA concentration. I^2^ (95% CI) was 69% (36%, 85%) for CVD, 77% (37%, 92%) for CHD and 27% (0%, 92%) for stroke. BRUNECK indicates Bruneck Study; CHD, coronary heart disease; CVD, cardiovascular disease; DHS, Dallas Heart Study; GetABI, German Epidemiological Trial on Ankle Brachial Index; KAROLA, Langzeiterfolge der KARdiOLogischen Anschlussheilbehandlung; PAD, peripheral arterial disease; RRs, risk ratios; SDMA, symmetric dimethylarginine.](jah30004-e001833-f6){#fig06}

Discussion
==========

The present review of about 20 000 non-overlapping participants from 22 prospective cohort studies across 9 countries has assessed strength and consistency of associations between circulating levels of ADMA and SDMA concentration and subsequent risk of cardiovascular outcomes. Overall, compared with individuals in the bottom third of baseline ADMA concentration, those in the top third of baseline ADMA concentration were at a ≈40% higher risk of CVD. This association was similar in participants with and without pre-existing CVD or kidney disease at baseline and across studies that used diverse methods to measure dimethylarginine levels. On the basis of somewhat limited existing data on SDMA, there was no significant association between SDMA concentration and the risk of cardiovascular outcomes.

Our epidemiological findings lend support to the suggested pathophysiological role of ADMA in atherogenesis. ADMA inhibits the production of nitric oxide (NO), a potent vasodilatator, from [l]{.smallcaps}-arginine.[@b3],[@b54] Accordingly, mice with genetically and chemically elevated levels of ADMA exhibit prompt increases in systemic vascular resistance and blood pressure[@b55],[@b56], whereas mice with low ADMA levels show decreases in these parameters.[@b57] In addition to the effect on vascular tone, it has been proposed[@b54],[@b58] that the combination of high ADMA and low NO may promote vascular inflammation,[@b59]--[@b62] low density lipoprotein oxidation,[@b63] smooth muscle cell proliferation,[@b64] endothelial cell apoptosis,[@b65] generation of free radicals,[@b66] and adhesion and aggregation of platelets.[@b67],[@b68] In the Framingham Study, elevated ADMA levels were associated with a higher risk of MRI-detected silent brain infarcts.[@b69] Furthermore, compelling evidence from randomized controlled trials indicates that [l]{.smallcaps}-arginine supplementation reduces blood pressure[@b70] and may recuperate vascular endothelial function.[@b71] Altogether, ADMA and NO are regarded to play a pivotal role in endothelial dysfunction, the essential first step in atherogenesis.

On the other hand, despite its structural similarity to ADMA, the somewhat discrepant findings for SDMA may be explained by the notion that function and metabolism of SDMA are different. SDMA has very limited or no inhibitory effect on NO synthase.[@b72] While \>80% of circulating ADMA is eliminated through enzymatic degradation by the enzyme dimethylarginine dimethylaminohydrolase (DDAH),[@b73] SDMA is primarily eliminated through renal filtration.[@b74] A meta-analysis of 18 studies suggested that SDMA strongly correlates with both measured and estimated glomerular filtration rate and therefore can be regarded as an endogenous marker of renal function.[@b75] Nonetheless, it is also possible that the apparent lack of significant associations for SDMA observed in the current review is due to low statistical power because concurrent data on this marker were available in only a handful of studies.

The strengths and limitations of our study merit consideration. We present the first meta-analysis on circulating ADMA and SDMA concentrations in relation to subsequent risk of cardiovascular outcomes. We applied pre-defined inclusion criteria to identify solely prospective, long-term studies (\>1 year follow-up), thereby limiting potential misleading results owing to "reverse causation". In the absence of individual-participant-level data, we used standardized estimates of ADMA and SDMA to allow consistent comparisons, and focused on clearly defined cardiovascular outcomes to meaningfully characterize the etiological associations. We have also presented data on a wide range of clinically relevant subgroups, which allowed us to explore in detail any potential sources of heterogeneity.

Nevertheless, our meta-analysis was still limited by the moderate amount of available data on cardiovascular outcomes. For example, there were only around 400 stroke events recorded among the ADMA studies. All studies measured dimethylarginines only once at baseline and were therefore unable to assess within-person variability of these biomarkers over time.[@b76] Given these limitations in the existing literature, further investigation in large general population studies is needed, which would enable: (1) a further increase in the precision of estimates; (2) characterization of the shape of any dose-response relationships; (3) direct comparison of the magnitude of effect sizes for ADMA to those for traditional cardiovascular risk factors; (4) a more consistent approach to statistical adjustment; and (5) exploration of usefulness of these markers in CVD risk prediction by calculation of risk prediction metrics such as risk discrimination and risk reclassification. Finally, our meta-analysis was based on published data from prospective observational studies and therefore does not allow inferences to be made on the causal involvement of ADMA in cardiovascular disease development. Intervention studies that specifically target ADMA-related pathways (eg, via [l]{.smallcaps}-arginine and DDAH) will help judge causality.[@b77],[@b78] Furthermore, genetic loci discovered in recent genome-wide association studies of circulating levels of ADMA[@b79],[@b80] should provide further opportunities to evaluate specifically the causal association of ADMA with CVD through the "Mendelian randomization" approach[@b81] (in analogy to the existing evidence for a causal role of NO signaling in the development of myocardial infarction[@b82]).

In conclusion, available evidence suggests significant positive associations of ADMA with cardiovascular disease outcomes under a broad range of circumstances. Further research is needed to better clarify these associations, particularly in large general population studies.
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